Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

A legfontosabb adatok

Ki végzi
Spectral Diagnostics (US) Inc.
Hol
Ann Arbor, Atlanta, Birmingham, Boulder, Camden, Charleston, Chattanooga, Houston, Little Rock, New York, Piscataway, Pittsburgh, Rochester, San Antonio, San Francisco, Shreveport, Springfield, Stony Brook és Washington D.C. (Egyesült Államok)Mind a 20 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
157 fő vett részt
Kezdés
2020. jan. 9.
Befejezés
2026. febr. 10.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
A regiszteradat frissítve
2026. október 13.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years of age
  • Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours; Norepinephrine > 0.05mcg/kg/min; Dopamine > 10 mcg/kg/min; Phenylephrine > 0.4 mcg/kg/min; Epinephrine > 0.05 mcg/kg/min; Vasopressin > 0.03 units/min; Vasopressin (any dose) in combination with another vasopressor listed above
  • The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility
  • Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration
  • The subject must have a screening multi-organ dysfunction score (MODS) >9 OR a sequential organ failure assessment (SOFA) >11, in the event a complete MODS cannot be obtained due to missing measurements
  • Endotoxin Activity Assay between ≥ 0.60 to <0.90 EA units
  • Evidence of at least 1 of the following criteria for new onset organ dysfunction that is considered to be due to the acute illness:; Requirement for positive pressure ventilation via an endotracheal tube or tracheostomy tube; Thrombocytopenia defined as acute onset of platelet count <150,000µ/L or a reduction of 50% from prior known levels; Acute oliguria defined as urine output <0.5mL/kg/hr for at least 6 hours despite adequate fluid resuscitation

Ki nem vehet részt

  • Inability to achieve or maintain a minimum mean arterial pressure (MAP) of ≥ 65mmHg despite vasopressor therapy and fluid resuscitation
  • Subject is currently enrolled in an investigational drug or device trial
  • Subject has been previously enrolled in the current trial
  • Subject has end-stage renal disease and requires chronic dialysis
  • Subject has had an acute myocardial infarction (AMI) within the past 4 weeks
  • Subject has uncontrolled hemorrhage (acute blood loss requiring > 3 UPC in the past 24 hours)
  • Known hypersensitivity to Polymyxin B
  • Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia (H.I.T.)
  • Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end-stage chronic illness (eg. lack of source control and bowel necrosis) with no reasonable expectation of survival to hospital discharge
  • There is clinical support for non-septic shock such as:; Acute pulmonary embolus; Transfusion reaction; Severe congestive heart failure (e.g. NYHA Class IV, ejection fraction < 35%)
  • Subject has severe granulocytopenia (leukocyte count less than 500 cells/mm3) or severe thrombocytopenia (platelet count less than 30,000 cells/mm3)
  • HIV infection in association with a last known or suspected CD4 count of <50/mm3
  • Inability to obtain an informed consent from the subject, family member or an authorized surrogate
  • Lack of commitment for full medical support
  • Subject has had chest compressions as part of CPR during this hospitalization without immediate return to communicative state
  • Major trauma within 36 hours of screening
  • Subject's baseline state is non-communicative
  • Subject has sustained extensive third-degree burns within the past 7 days
  • Body weight < 35 kg (77 pounds)

Helyszínek itt: Egyesült Államok

  • University of MichiganAnn Arbor, Egyesült Államok
  • Emory UniversityAtlanta, Egyesült Államok
  • University of Alabama at BirminghamBirmingham, Egyesült Államok
  • Pulmonary AssociatesBoulder, Egyesült Államok
  • Cooper Health SystemCamden, Egyesült Államok
  • Medical University of South CarolinaCharleston, Egyesült Államok
  • CHI MemorialChattanooga, Egyesült Államok
  • Parkridge HospitalChattanooga, Egyesült Államok
  • The University of Texas Health Science Center at HoustonHouston, Egyesült Államok
  • University of Arkansas for Medical SciencesLittle Rock, Egyesült Államok
  • Mt Sinai HospitalNew York, Egyesült Államok
  • Rutgers, the State University of New JerseyPiscataway, Egyesült Államok
  • UPMCPittsburgh, Egyesült Államok
  • Mayo ClinicRochester, Egyesült Államok
  • Institute for Extracorporeal Life SupportSan Antonio, Egyesült Államok
  • University of California San FranciscoSan Francisco, Egyesült Államok
  • Louisiana State University Health ShreveportShreveport, Egyesült Államok
  • Baystate Medical CenterSpringfield, Egyesült Államok
  • Stony Brook UniversityStony Brook, Egyesült Államok
  • George Washington UniversityWashington D.C., Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

A vizsgálat 2 csoportja

  • PMX TreatmentA vizsgált kezelés

    Standard medical care for septic shock plus treatment with the PMX cartridge (twice approximately 24 hours apart)

    Kezelés: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge

  • ControlNincs vizsgálati kezelés, összehasonlításként

    Standard medical care alone

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of PMX Cartridge in Addition to Standard Medical Care for Patients With Endotoxemic Septic Shock
Publikációk
A regiszteradat frissítve
2026. október 13.